Myriad Genetics Inc (NAS:MYGN)
$ 26.885 0.495 (1.88%) Market Cap: 2.44 Bil Enterprise Value: 2.44 Bil PE Ratio: 0 PB Ratio: 3.30 GF Score: 78/100

Myriad Genetics Inc at JPMorgan Healthcare Conference Transcript

Jan 13, 2020 / 11:00PM GMT
Release Date Price: $28.13 (+0.04%)
Tycho W. Peterson
JP Morgan Chase & Co, Research Division - Senior Analyst

Okay. Good afternoon. We're going to go ahead and kick it off. I'm Tycho Peterson from the Life Science team. It's my pleasure to introduce our next company, Myriad. We'll do a breakout right after in the Olympic Room. So with that, let me turn it over to Mark Capone.

Mark Christopher Capone
Myriad Genetics, Inc. - CEO, President & Director

Good afternoon, and thank you, Tycho. Thank you for JP Morgan, once again, hosting an excellent and popular conference. Welcome to the Myriad Genetics corporate presentation. Just as a reminder, this presentation may contain forward-looking statements, and we would refer you to our detailed SEC filings on our website.

At Myriad, our vision is to be a trusted adviser, transforming patients' lives worldwide with pioneering molecular diagnostics. Or as we say, in short, we would like to be the global leader in precision medicine. Now precision medicine offers the promise of accomplishing the dual lanes, and that is achieving better

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot